C-PPW7Neuraly
glial activation inhibition, GLP-1R agonism, neuroinflammation
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PPW7
C-PPW7C-PPW7glial activation inhibition, GLP-1R agonism, neuroinflammation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety, tolerability, PK and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). The study will be conducted in 2 Parts (Part A and B), with up to 8 cohorts included in each part (Part A; Cohorts A1 to A8 and Part B; Cohorts B2 to B8).
This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders.
This is a Phase 2a study designed to assess the effect of NLY01 in patients with type 2 diabetes. Patients will be monitored for safety, pharmacokinetics, and pharmacodynamic effects on glycemic control.
ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson's Disease | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Pipeline — Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Pipeline NLY01 Drug Candidate NLY01 Summary First-in-Class GLP-1R agonist for Neurodegenerative Disease Mechanism of Action Long-acting, microglia-targeted GLP-1R agonist Indication Parkinson’s Disease (NLY01-PD) Alzheimer’s Disease (NLY01-AD) Development Stage Phase II Description NLY01 is a pegylated exendin-4 analogue of Glucagon Like Peptide-1 Rece
HSRAA26 – HSRAA Skip to content Menu Close Home About us Meet the Board & Committee Become a Member Resources Let’s Talk Training News Contact us HSRAA Conference Previous Conferences HSRAA26 – Manchester HSRAA24 – Edinburgh HSRAA23 – Dublin Basket Login Search for: Menu Home About us Meet the Board & Committee Become a Member Resources Let’s Talk Training News Contact us HSRAA Conference Previous Conferences HSRAA26 – Manchester HSRAA24 – Edinburgh HSRAA23 – Dublin Basket Login HSRAA26 4th–6th March 20 … clinical trials. Advanced Technology: Secure online access to manage inventory, submit work requests, and generate custom reports. Comprehensive Compliance: GxP-compliant SOPs and rigorous QA standards ensure regulatory confidence. We safeguard everything from cell banks and bio samples to blocks, slides, test articles, and electronic media. Our mission is simple: We don’t just store—we take care. Website https://eplarchives.com/ Register Now Book your place to join us in Man
Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson’s Disease – Boston Harbor Angels Search Home About Us Celebrates 20 Years of Angel Investing Letter to Founders Facts Management Team Internship Program For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner For Founders What Industries? Where Do We Invest? Apply! Schedule Consultation with Z! Boston Harbor Angels Lighthouse What Founders Say! Portfolio Portfolio Store News News LinkedIn Media Podcast Contact Us Home About Us … anagement Team Internship Program For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner For Founders What Industries? Where Do We Invest? Apply! Schedule Consultation with Z! Boston Harbor Angels Lighthouse What Founders Say! Portfolio Portfolio Store News News LinkedIn Media Podcast Contact Us Home News Portfolio News Neuraly Announces Topline Results from Phase 2 Trial of NLY01 in Parkinson& … e About Us Portfolio News Contact For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner Follow Us Facebook Linkedin Copyright © 2023. Boston Harbor Angels. All Rights Reserved. This website is created and maintained by Business IT Essentials Manage Cookie Consent We use cookies to optimize our website and our service. Functional Functional Always active The technical storage or access is
Pitch Contest in Respiratory Disease - Jury - New Aurameeting ABOUT REGISTRATION SUBMIT YOUR APPLICATION JURY PITCH CONTEST IN RESPIRATORY DISEASE Jury – Coming soon The evaluation panel will consist of industry and academic experts from the University of Parma, Chiesi Farmaceutici, Deloitte and startup companies , who will assess the projects at the end of the pitch sessions. Projects will be assessed based on predefined evaluation criteria , as defined in the Contest Regulation. David Edwards ( SC Therapeutics, US ) David A. Edwards is a long-standing professor of th … including Creating Things That Matter (Holt), winner of the 2018 Nautilus Book Award for the category of creativity. Close Justin Hanes (Johns Hopkins University, US) Dr. Hanes the Lewis J. Ort Professor and founding Director of the Center for Nanomedicine at the Johns Hopkins University School of Medicine, where he holds faculty appointments in the departments of Ophthalmology (primary), Biomedical Engineering, Chemical & Biomolecular Engineering, Neurosurgery, Oncology … arts of the body. He is the most recent recipient of the Thomas T. Mercer Joint Prize in pharmaceutical aerosols and inhalable materials from AAAR and ISAM. He is an inventor on more than 180 US patents and patent applications focused in the area of advanced delivery systems that make drugs and gene therapies safer and more effective. Technologies he developed with co-inventors have served as the basis for the launch of several companies, including Advanced Inhalation Researc … since the genesis of the company, including as Chief Scientist of the Nexus II fund. He has served on the scientific advisory boards for pharmaceutical companies, including Genentech in the Drug Delivery Division and ReCode Therapeutics, and he is a past chair of the Gene and Drug Delivery Study Section of the National Institutes of Health. He has served as the President of the Controlled Release Society and he is a fellow of several scientific societies. Dr. Hanes has recei … r early professional career commenced at INIA in Madrid, followed by a research scholarship at the Plum Island Animal Disease Center (USDA-ARS) in New York, where she contributed within a distinguished, international scientific community engaged in the study of the African Swine Fever virus. Subsequently, she conducted research in Nairobi, Kenya,
Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders | BioBuzz All Regions All Regions BioHealth Capital Region Greater Philadelphia Research Triangle Park News Events BioCatalyst Program Sign Up BioHealth Capital Region Industry Trends Press Release Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders By Sharlene Brown, PhD · Published December 3, 2019 · 7 min read · BioHealth Capital Region ← News / Why The Next Biotech Boom Could be Sparked… Several Maryland Biotech Firms Are Blazing New Trai … lle, Maryland announced the FDA clearance of its investigational new drug (IND) application for its oral glia-to-neuron conversion drug, NNI-362, in May 2019 and began placebo-controlled Phase IA trials in August 2019. The company, founded by CEO Judith Kelleher-Andersson, PhD, received $2.5M in the fall of 2018 from the National Institute on Aging (NIA) and is expected to report primary outcomes in April 2020. Howard Federoff, M.D., PhD, and faculty member at the University
Justin Hanes, Ph.D. Home Strategies Overview Private Equity Structured Opportunities Public Equities Co-Investments Portfolio Team News Investor Login SEI Login MSFS Login Investor login SEI Login MSFS Login [Our Team] Venture Partner Justin Hanes, Ph.D. Director, Center of Nanomedicine at Johns Hopkins Medicine Nanomedicine EDUCATION BS – University of California Los Angeles PhD – Massachusetts Institute of Technology AWARDS AND ACCOLADES National Academy of Inventors, 2014 The World’s Most Influential Scientific Minds / Highly Cited Researcher” by Thompson Reuters MIT Technology Revi … ation by replying HELP. Message frequency varies and message and data rates may apply. You may review our Privacy Policy to learn how your data is used. Thank you! Your submission has been received! Something went wrong while submitting the form, please try again. Information Terms of Use Privacy Policy Security For Investors SEI Login MSFS Login Thank you! Submission received! Something went wrong, try again. ↑ Catalio Capital Management, LP | © 2026
Congratulations to our Clients! - Shulman Rogers Skip to content Careers Contact Us About People Business Services Personal Services The Latest About Shulman Rogers About Shulman Rogers Diversity Community Careers Our People View All Attorneys Attorneys Paralegals Key Administrative Staff Careers Business Services and Industries View All Business Services & Industries Business and Financial Services Cannabis Law Commercial Lending Employment and Labor Law Entertainment Law Government Contracts Hospitality Law Intellectual Property Litigation Mergers and Acquisitions Startups and Emerging G … st 45 days! Neuraly Inc. received FDA clearance for an investigational new drug application for patients with Alzheimer’s and Parkinson’s disease. Adaptive Phage Therapeutics is deploying its investigational PhageBank™ therapy in response to a deadly outbreak of secondary infections in COVID-19 patients with expectations of reducing mortality rates by over 30%. APT also received FDA orphan drug designation for the treatment of prosthetic joint infections (PJI) utilizing Phage
The road ahead: 2022 – The Science of Parkinson's Skip to content The Science of Parkinson's Plain English information about the research being conducted on Parkinson's Menu About Alpha Synuclein Dopamine Genetics of PD Lectures Previous posts Tremor What is Parkinson’s? The road ahead: 2022 January 20, 2022 October 27, 2022 ~ Simon # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s. It is an exercise in managing ex … efficacy. In July of 2020, the US FDA cleared an Investigational New Drug (IND) application for DNL151/ BIIB122 enabling an expansion of Denali’s clinical trial program. Biogen and Denali have recently announced their plans for future development of DNL151/ BIIB122 ( Source ). There will be two studies: The first trial will be called the “LIGHTHOUSE study” and it will be a global Phase III clinical trial. The companies are hoping to recruit 400 people with P … y 2022, Caraway Therapeutics announced that they have received a third research grant from the Michael J Fox Foundation to continue advancement of TRPML1 agonists for GBA-associated Parkinson’s ( Source ) . French gene therapy company Lysogene have a GBA-focused discovery programme ( Source ). Danish biotech company Orphazyme has had a successful year with their lead candidate, the heat shock protein co-activator arimoclomol . The company is applying for regulatory appr … ompany focused on identifying drug targets for Parkinson’s. They were awarded a grant from the Michael J Fox Foundation to accelerate a PARKIN activator program ( Source ). PARKIN is a protein that has many functions, and disruption of it is associated with increased risk of developing Parkinson’s. Another company developing a PARKIN-focused approach is a Korean company called Cellivery , which is developing a cell-permeable form of PARKIN (iCP-Parkin). In 2020, the com … n interest in PARKIN activation is Progenra . In 2020, they received a research grant from the Michael J Fox Foundation to accelerate their PARKIN activator program. Deubiquitinating (DUB) enzyme inhibitors: Deubiquitinating enzyme make the removal of damaged mitochondria more difficult. Inhibiting them is viewed as a means of stimulating mitopha
Aging Companies (for profits) - Google Sheets Die Datei kann in Ihrem Browser nicht geöffnet werden, weil JavaScript nicht aktiviert ist. Aktivieren Sie JavaScript und laden Sie die Seite noch einmal. Diese Browserversion wird nicht mehr unterstützt. Installieren Sie bitte einen unterstützten Browser. Aging Companies (for profits) Tab Extern Freigeben Anmelden Datei Bearbeiten Ansicht Einfügen Format Daten Tools Erweiterungen Hilfe Bedienungshilfen Fehlerbehebung Nicht gespeicherte Änderungen in Drive &n … NA interference (RNAi) therapieus to silence disease-specific genes, with broad application to many age-related disease areas FDA approved Tx proteostasis (h)ATTR(-CM), AD, HD, ALS, T2D, MASH, NAFLD, hypercholesterolemia, hypertension humans 82 ATTR, APP, PCSK9, AGT, HTT, SOD-1, HSD17B13 siRNA pharma Yvonne Greenstreet, Kevin Fitzgerald Boston yes ALNY $38,902 2100 2442 2002 >$100M Onpattro, Amvuttra, Leqvio science presentations 2025-02-02 2024-08-15 *Borderline: Broad pr
%PDF-1.5 %���� 2 0 obj > endobj 61 0 obj > stream x�+��| endstream endobj 62 0 obj > stream x�%�; �0�=�;A�ٍJZ�S+{��`D�o@^100�"?�p�B��n��� y[� �!v,�(؉&��5D > stream x�%�� 1E��B����d�I6�vq��Lj VP�q��w@.��yP��w������0��읗�Gx'��XS�!a����u%C �m�����on)ӑ�t7�h4�hAkZRc]Y� ��� �84 endstream endobj 65 0 obj > stream x��\[o۸~�����]4�x��b�@�x۴��8n����v�ip��'I�����3�Pv슴�۶�*K$����pf(����ǧ���"��'��`_ �����G;>��� ��O��Nd9v�{'�&s�w6QVX��H��˃�V `*��Y��L �ǓY��[�U�ڤ��+}��Rr�(���(n1J�%�wTt�����C�r�h*��a�x��m O�,SD�. ,��C9�Rf� � ��S S�tئ���.����q(�,��bte���J�r��+k�GRD�\(RUb … Sh=e*}�lR�|p7��Ph�)�u�y��O{�_J���H,r�tW�|bR˕O��8��8n%A] ��T� c�#+�X���RFp84�,�_��)P3 -��Ғ�n] VO��H`n1fY�RB� -��Ғ�n]`ӳ �g �B�� �j���$�N � i�K��+��g@�㳌%�ܕ��� ,])�,�Yf�/$�N � ��|=-y����fɳ;x��qY��ޟl+IwUbj%�y��>IfC9we�-٪T�=�ʂa�Sb�?������� 3/���K�hϺOƶb���i;�%�U)�d�� v� �/�G3�8�(?���s H?o 8�G��;�|��3�#��P'�F������dž\���� �I�?�L9 �N� J`� �*fq���H�#��)��e:� ��X�S��8[� z>��0�� O ����[�%��s��>�3�zn�d�-f2��Y�pc1H�a�2t��LT1 Y�� ��\�&
News — Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact News MAY 5, 2026 Neuraly Inc. Supports Phase 2 Investigator-Initiated Trial of Pegsebrenatide (NLY01) for Progressive Multiple Sclerosis Neuraly Inc., a wholy owned subsidiary of D&D Pharmatech, Inc. (KOSDAQ: 347850), announced that the first patient has been dosed in a Phase 2 Investigator-Initiated Trial evaluating pegsebrenatide, Neuraly’s long-acting GLP1 recept … Article APR 27, 2021 Renowned scientist Dr. Ted Dawson to receive Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research Van Andel Institute has chosen internationally recognized Parkinson’s disease expert Ted Dawson, M.D., Ph.D, to receive its 2021 Jay Van Andel Award for Outstanding Achievement in Parkinson’s Disease Research. Full Article MAR 5, 2021 Qi Cui, AGS 2021: The GLP-1R Agonist NLY01 Reduces Neuroinflammation and Protects against RGC Loss … other retinal diseases Full Article NOV 2, 2020 Receiving FDA Clearance of IND Application to Initiate Phase 2B Trial of NLY01 for Patients with AD Neuraly announced it has received clearance of an investigational new drug application (IND) to initiate a Phase 2B trial of NLY01 in patients with Alzheimer’s disease. Full Article MAR 3, 2020 Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease Neuraly, a clinical stage … ors for Parkinson's disease with aims to file an investigational new drug (IND) application with the FDA next year. Full Article Privacy Policy © Copyright 2023, Neuraly Inc 704 Quince Orchard Road #320 Gaithersburg, MD 20878 240.937.5880 [email protected]
Five Female Investors Who Are Making Their Mark in Life Science | I95 Business Five Female Investors Who Are Making Their Mark in Life Science | I95 Business Skip to main content person_outline Login search Search None Doing Business Organizations Mergers + Aquisitions Inclusion + Belonging COVID-19 Cannabis Strategies Business Services Banking + Investments Accounting + Finance Legal + Transactions HR + Workplace Money + Wealth Insurance + Planning Innovation + Technology ESOs Artificial Intelligence Manufacturing + 3-D Printing Entrepreneurs + Startups Investors + Mentors Technology Venture … growing within the BHCR at the same time several prominent female investors and fund directors are making their mark on the field. If you’ve been making the rounds at regional events like TEDCO’s Entrepreneur Expo, BioHealth Innovation’s (BHI) BioHealth Capital Region Forum or the Maryland Tech Council’s Bioinnovation Conference, sessions and panels involved these VC thought leaders are can’t miss. Here are the five trailblazing investors shaping … enior management team of MASA Life Science Ventures (MLSV) where she co-led the fund’s investment strategy and managed several MLSV portfolio investments through successful exits. She was also the Chief Financial Officer at Oncologix, an early-stage biotech that was sold to Antigenics, Inc. Sirinakis serves on the boards of the Tech Council of Maryland and on the Investment Committees for Virginia’s Center for Innovative Technology BioLife Fund and the Ivy Foundat … A in Maryland. Claire Broido Johnson, Managing Director, Maryland Momentum Fund Claire Broido Johnson leads the Maryland Momentum Fund (MMF), a $10M investment fund that supports early-stage companies affiliated with the University System of Maryland (USM). The MMF provides investment funding for promising technology ventures that emerge from USM’s 12 institutions. The MMF has invested in up-and-coming BHCR life science companies Gemstone Therapeutics, Veralox Ther … sified, 41-year-old VC firm that is currently investing out of its $3.3B NEA 16 fund, $1B of which will be deployed in the biopharma space. NEA investments run the gamut from seed rounds all the way through crossover rounds pre-IPO, with a focus on rare diseases and oncology. 50% of NEA’s investments would be considered early-stage investme
10th Antifibrotic Drug Development Summit Skip to content The site is part of the Hanson Wade division at Hanson Wade Group . About Us | Products | Contact Us Hanson Wade Conferences Limited is registered in England & Wales, number 16983906. Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH. Hanson Wade This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2025 summit. Returning in 2026 About About Event Events in the Series Hanson Wade Products What’s On? Full 2025 Event Guide 2025 Speakers Why Partner Why Partner Pa
About us - New Aurameeting FIND MORE Who we are Staff Client Feedback SERVICES Events Digital Events Association Management CME SECRETARIAL SERVICES Contact Events calendar Current Events Events Archive Cart This is milan Login Select Page About us Established by the Celli family, NEW AURAMEETING started as a travel agency in the historical Fiera di Milano, supported by the good reputation in the tourism sector earned by three Celli generations. New Aurameeting shifted gradually towards the organisation of events and conferences and its evolution was complete as it celebrated its 30th annivers … including Creating Things That Matter (Holt), winner of the 2018 Nautilus Book Award for the category of creativity. Close Justin Hanes (Johns Hopkins University, US) Dr. Hanes the Lewis J. Ort Professor and founding Director of the Center for Nanomedicine at the Johns Hopkins University School of Medicine, where he holds faculty appointments in the departments of Ophthalmology (primary), Biomedical Engineering, Chemical & Biomolecular Engineering, Neurosurgery, Oncology … arts of the body. He is the most recent recipient of the Thomas T. Mercer Joint Prize in pharmaceutical aerosols and inhalable materials from AAAR and ISAM. He is an inventor on more than 180 US patents and patent applications focused in the area of advanced delivery systems that make drugs and gene therapies safer and more effective. Technologies he developed with co-inventors have served as the basis for the launch of several companies, including Advanced Inhalation Researc … since the genesis of the company, including as Chief Scientist of the Nexus II fund. He has served on the scientific advisory boards for pharmaceutical companies, including Genentech in the Drug Delivery Division and ReCode Therapeutics, and he is a past chair of the Gene and Drug Delivery Study Section of the National Institutes of Health. He has served as the President of the Controlled Release Society and he is a fellow of several scientific societies. Dr. Hanes has recei … r early professional career commenced at INIA in Madrid, followed by a research scholarship at the Plum Island Animal Disease Center (USDA-ARS) in New York, where she contributed within a distinguished, international scientific community engaged in the study of the African Swine Fever virus. Subsequently, she conducted research in Nairobi, Kenya,
Ventyx Biosciences Enters New Chapter with Eli Lilly Acquisition | Ventyx Biosciences posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si … n the company for future growth. Upcoming Catalysts: - Submission of regulatory application for EVX-04 by year-end 2026. - Additional biomarker and immunogenicity data for EVX-01 expected in 2026. - Development updates on autoimmune disease programs anticipated in 2026. 👇 **Read the full Stock Analysis:** #HealthCare #Earnings #Investing #SellSyde #StockMarket 2 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 6,998 followers View Profile Connect
Live Team Training for Parkinson's 2024 | Parkinson's Foundation Learning Lab Jump to content Parkinson's Foundation Learning Lab Search Open menu Cart My Courses Log in Register Bookmark/Search this post Facebook X LinkedIn Forward Home Education Hubs Professional Education Live Professional Education Community Education Volunteer Education Formación en español Special Programs Team Training *NEW* Student Corner Community Partners in Parkinson's Care Edmond J. Safra Nurse Educator Program Exercise & Movement Education Accreditation Recognition Tools and Resources Español About You ar … ltant for Amneal Pharmaceuticals, Biogen, Eisai, Kyowa Kirian; the recipient of Grant/Research support from Addex, Axsome, Bukwang, Cerevel, Neuraly, Pharma2b, Roche Diagnostics, Takeda, UCB; is on a Speaker' Bureau for Amneal, Biogen, Kyowa Kirin. Sotirios Parashos, MD: has disclosed that he has is a grant recipient/researcher support for Bukwang Pharmaceutical, Inhibikase Pharmaceutical, Intra-Cellular Therapies, Neuraly, SunPharma, UCB, Abbvie, Amnion, NeuroGlove and has a … relationships to disclose Sotirios Parashos, MD: has disclosed that he has is a grant recipient/researcher support for Bukwang Pharmaceutical, Inhibikase Pharmaceutical, Intra-Cellular Therapies, Neuraly, SunPharma, UCB, Abbvie, Amnion, NeuroGlove and has a stockholder of Abbott Laboratories. Planner(s) Denise Beran: has no relevant financial relationships to disclose Elizabeth Pollard: has no relevant financial relationships to disclose In support of improving patient care, … ation has been authorized by the American Nurses Credentialing Center (ANCC) to award CNE credit. This activity is designated for 27.00 CNE credits. Participants should only claim credit commensurate with the extent of their participation. Physician Assistants Parkinson’s Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 27.00 AAP
Xoc Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 05 Mar 2026 Xoc Pharmaceuticals, Inc. Private Company | 2013 | California, United States | 10-50 | xocpharma.com Private Company | 2013 | California, United States | 10-50 | xocpharma.com Last update 05 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Endocrinology and Metabolic Disease Small molecule drug Disease domain score A glimpse into the focuse … een INP104, IV DHE and Migranal are the final clinical requirements to New Drug Application later this year. Zosano Pharma – In December 2019, California-based Zosano Pharma Corporation submitted its New Drug Application to the FDA for Qtrypta, a potential treatment for acute migraine. The company is planning for the FDA to accept the NDA by March 2020. The filing was based on results from the pivotal Phase II/III ZOTRIP trial, in which 41.5% of patients treated with Qtrypta … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Licensing Deals in Biotechnology 2020-2026 - Research and Markets Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscription … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … Forecasts, Till 2035 - Distribution by Source of Cell Line / Expression System, Application of Cell Line, Company Size, and Key Geographical Regions  Report 455 Pages December 2025 Global From €4311 EUR $4,799 USD £3,730 GBP This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user … ng Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
Boston Harbor Angels Awards Portfolio Companies at Annual Meeting – Boston Harbor Angels Search Home About Us Celebrates 20 Years of Angel Investing Letter to Founders Facts Management Team Internship Program For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner For Founders What Industries? Where Do We Invest? Apply! Schedule Consultation with Z! Boston Harbor Angels Lighthouse What Founders Say! Portfolio Portfolio Store News News LinkedIn Media Podcast Contact Us Home About Us Celebrates 20 Years of An … anagement Team Internship Program For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner For Founders What Industries? Where Do We Invest? Apply! Schedule Consultation with Z! Boston Harbor Angels Lighthouse What Founders Say! Portfolio Portfolio Store News News LinkedIn Media Podcast Contact Us Home News Portfolio News , Organization News , Press Release Boston Harbor Angels Awards Portfolio C … portfolio companies at its annual end-of-year general meeting. Exit of the Year Award: Corbus Pharmaceuticals on NASDAQ Biotech Startup of the Year Award: Astrocytes Pharmaceuticals Inc. IT Startup of the Year Award: Wasabi The meeting featured interviews with Yuval Cohen, CEO of Corbus Pharmaceuticals and Mark Tepper, President & Chief Scientific Officer of Corbus Pharmaceuticals; and David Friend, CEO and co-founder of Wasabi. The group also honored Mic Williams, Presid … et, aviation, etc. We believe we contribute more than money to the companies we fund and welcome the opportunity to work with entrepreneurs who are open to taking advice, yet have the smarts and determination to make their company successful. Share this post Facebook Twitter LinkedIn Google + Email Related Posts 22 Jun June 22, 2018 Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference Corbus Pharmaceuticals Holdings, Inc., … e About Us Portfolio News Contact For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner Follow Us Facebook Linkedin Copyright © 2023. Boston Harbor Angels. All Rights Reserved. This website is created and maintained by Business IT Essentials Manage Cookie Co
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Biogen Acquires Apellis for $5.6B, Expands Immunology Focus | Mark A Ohrvall posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo
Neuraly, Inc. - Job Opportunities In order to use this site, it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser . You are using an unsupported browser. We've listened to your feedback and have made some great improvements to the Paylocity experience. Unfortunately, it looks like your current browser is outdated and incompatible with those features. Update your browser today to unlock the new experience. It's true, there are many great reasons to update your browser: Security - Stay protected against scams, viruses, and threats Speed - E
News Archive | TEDCO Skip to main content MyTEDCO Hamburger About TEDCO Our Team Jobs at TEDCO Request for Proposals Portfolio Contact Us MyTEDCO Funding Cultivate Maryland Equitech Growth Fund Federal Programs DefTech Federal Labs Leveraging Innovation to Products (FLLIP) Pilot Program SBIR/STTR Proposal Lab SBIR/STTR Matching Funds Makerspace Program Maryland Innovation Initiative Baltimore Innovation Initiative (BII) Maryland Stem Cell Research Fund Other Funding Ag and Rural Rebuild (ARR) Challenge RUBRIC Program Rural Business Innovation Initiative Fund Seed Funds Social Impa … ment & Marketing Equal Access Initiative Federal Programs DefTech SBIR/STTR Proposal Lab SBIR/STTR Technical Assistance Technical and Business Assistance (TABA) APEX Accelerator Finance & Technology Government Program Development, Affairs & Policy Cultivate Maryland Cyber Maryland Program Institute for Women Entrepreneur Excellence, Inc. Market Search Rural Business Innovation Initiative TEDCO Dashboard Urban Business Innovation Initiative Venture Development Conc … orm by IPGen Network Advisors Prelude Pitch Pava LaPere Innovation Acceleration Grant Program Insights News & Events Press Releases News Archive Newsletters Events Calendar Events Archive TEDCO's 2026 Entrepreneur Expo --> Toggle navigation --> Main navigation Funding Resources Insights News & Events Hamburger About TEDCO Our Team Jobs at TEDCO Request for Proposals Portfolio Contact Us MyTEDCO Search Search Home News Archive Search News Archive Year - Any - 2026 … rchive Year - Any - 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 Apply Hogan is proposing legislation to invest $16 million in a new Maryland Technology Infrastructure Fund January 3, 2019 The Maryland Technology Infrastructure Fund to be housed at TEDCO LEARN MORE Money comes for Maryland tech startups December 28, 2018 Maryland took a couple of big steps forward in 2018 toward becoming the sleeping tech startup giant that many in the state think it can be. LE … s. LEARN MORE Following $100M sale of Harpoon Medical, veteran health tech exec fund raises for new venture December 21, 2018 Most of the angels who participated in ReGelTec's early funding round had also made money Harpoon Medical's $100 million sale. LEARN MORE Adaptive Phage Therapeutics Collaborates with Researchers at Yale University to Manu
424B4 1 d900229d424b4.htm 424B4 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-284225 PROSPECTUS 15,277,778 Shares Common Stock This is Metsera, Inc.’s initial public offering. We are selling 15,277,778 shares of our common stock. The public offering price is $18.00 per share. Currently, no public market exists for our common stock. Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “MTSR.” We are an “emerging growth company” and a “smaller reporting company& … ue its regulatory approval in the United States pursuant to a biologics license application, or BLA. MET-233i is a subcutaneously injectable ultra-long acting amylin analog, with enhanced solubility and miscibility with our other NuSH analog peptides, that we are developing for the treatment of obesity and overweight. We plan to develop MET-233i to be administered as a monotherapy or in combination with other NuSH analog peptides, including MET-097i. Based on preclinical stud … 3i support the ability to combine it with MET-097. Our Investigational New Drug application, or IND, for a Phase 1 clinical trial of MET-233i monotherapy in patients with obesity or overweight was cleared by the U.S. Food and Drug Administration, or the FDA. We have initiated this trial in the United States and plan to report preliminary data in mid 2025. If we are able to establish sufficient evidence of clinical safety in our MET-233i Phase 1 trial, we plan to initiate … like body weight loss with an oral therapy. In October 2024, our Clinical Trial Application, or CTA, was approved by Health Canada for a formulation optimization trial of our MOMENTUM oral peptide delivery platform using prototype compound MET-002, a predecessor peptide to MET-224o, and we have initiated dosing in that trial in Canada. In parallel to this formulation optimization trial, we plan to complete IND- and CTA-enabling studies of MET-224o, with a goal of allowing us … of Contents marketing approval of a drug is typically pursued under a new drug application, or NDA, and marketing approval of a biologic is pursued under a BLA. We believe there are potential benefits inherent in the biologic pathway, including that biologics may be eligible for 12 years of reference product exclusivity, while a novel compound r
Five Female Investors Who Are Making Their Mark in Life Science | BioBuzz All Regions All Regions BioHealth Capital Region Greater Philadelphia Research Triangle Park News Events BioCatalyst Program Sign Up BioHealth Capital Region Funding Five Female Investors Who Are Making Their Mark in Life Science By Steven Surdez · Published November 26, 2019 · 8 min read · BioHealth Capital Region ← News / Five Female Investors Who Are Making Their Mark… Five Female Investors Who Are Making Their Mark in Life Science November 26, 2019 Less than 10% of decision-maker … growing within the BHCR at the same time several prominent female investors and fund directors are making their mark on the field. If you’ve been making the rounds at regional events like TEDCO’s Entrepreneur Expo , BioHealth Innovation’s (BHI) BioHealth Capital Region Forum or the Maryland Tech Council’s Bioinnovation Conference , sessions and panels involved these VC thought leaders are can’t miss. Here are the five trailblazing investors shaping the futur … enior management team of MASA Life Science Ventures (MLSV) where she co-led the fund’s investment strategy and managed several MLSV portfolio investments through successful exits. She was also the Chief Financial Officer at Oncologix, an early-stage biotech that was sold to Antigenics, Inc. Sirinakis serves on the boards of the Tech Council of Maryland and on the Investment Committees for Virginia’s Center for Innovative Technology BioLife Fund and the Ivy Foundation (Univers … in Maryland. Claire Broido Johnson, Managing Director, Maryland Momentum Fund Claire Broido Johnson Claire Broido Johnson MBA, leads the Maryland Momentum Fund (MMF), a $10M investment fund that supports early-stage companies affiliated with the University System of Maryland (USM). The MMF provides investment funding for promising technology ventures that emerge from USM’s 12 institutions. The MMF has invested in up-and-coming BHCR life science companies Gemstone Thera … sified, 41-year-old VC firm that is currently investing out of its $3.3B NEA 16 fund, $1B of which will be deployed in the biopharma space. NEA investments run the gamut from seed rounds all the way through crossover rounds pre-IPO, with a focus on rare diseases and oncology. 50% of NEA’s investments would be considered early-stage investments.&n
3 Promising Maryland Biotechs that are Targeting Neurological Disorders | BioBuzz All Regions All Regions BioHealth Capital Region Greater Philadelphia Research Triangle Park News Events BioCatalyst Program Sign Up BioHealth Capital Region Industry Trends 3 Promising Maryland Biotechs that are Targeting Neurological Disorders By Rajamani Selvam · Published February 12, 2019 · 4 min read · BioHealth Capital Region ← News / 3 Promising Maryland Biotechs that are Targeting Neurological… 3 Promising Maryland Biotechs that are Targeting Neurological Disorders BrainSc … of its technology, in addition to private investment from the Maryland Venture Fund and Revolution LLC. BrainScope has been nominated twice, in 2017 and 2018, for the Prix Galien Foundation U.S.A Award for Best Medical Technology Product. BrainScope was also named as Maryland’s Emerging Life Science U.S. Business of the Year award winner in 2016. Developed using electroencephalogram (EEG) technology, advanced signal processing, machine learning technologies, and sophisticate … National Institute of Aging (NIA) awarded AgeneBio approximately $16 million to fund the phase pivotal 3 trial. AGB101 is a proprietary, extended release formulation of levetiracetam, an FDA-approved anti-epileptic drug, that targets overactivity in the hippocampus that can cause mild cognitive impairment (MCI) in patients with neurological disorders like Alzheimer’s. Another program in the AgeneBio pipeline is a GABA A -α5 positive allosteric modulator program, a late d … D Pharmatech with participating Korean venture funds. Locally, Maryland Venture Fund and Octave Life Sciences have also provided financing to the company. Most of the drugs available in the market are helpful to reduce or manage the symptoms but not for treating the disease. Neuraly is seeking to identify new drugs that can improve the lives of patients suffering from the disease, and their lead compound, NLY01, aims slow the disease progression by blocking glial cell
The Neuraly trial – The Science of Parkinson's Skip to content The Science of Parkinson's Plain English information about the research being conducted on Parkinson's Menu About Alpha Synuclein Dopamine Genetics of PD Lectures Previous posts Tremor What is Parkinson’s? The Neuraly trial November 5, 2019 November 10, 2019 ~ Simon This week a new clinical trial was registered which caught our attention here at the SoPD HQ. It is being sponsored by a small biotech called Neuraly and involves a drug called NLY01. NLY01 is a GLP-1R agonist – that
Biogen Acquires Apellis for $5.6B, Pivoting to Immunology | John Weber posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agre
Parkinson’s Disease Therapeutics Webinars | Parkinson's Disease JavaScript is currently disabled. Please enable JavaScript for an optimal experience. Skip to main content Animations Search Email Sign Up Log In Donate Now Home Page Are you looking for: ${result.term} Donate Now Menu Close Clear My Profile My Parkinson’s Library Log In Main navigation Why We Exist Why We Exist Our Mission Our Promise Our Impact Our Agenda Michael's Story Current Partnerships Parkinson's Research The State of the Field Our Research Strategy Key Research Initiatives Parkinson’s Biomarkers Prizes Understanding … on's Library Educational Guides For Researchers For Researchers Funding What We Fund Funding Opportunities Funded Studies Open Science & Research Integrity Resources Research Tools Data Resources Biospecimens Patient Engagement Research News Podcasts MJFF Scientific Publications Collaboration Collaborative Research Opportunities Industry Partners Working with Us Key Initiatives and Findings PPMI Clinical Study ASAP Initiative GP2 Take Action Take Action Donate Donate Now Ways
D&D Pharmatech --> D&D Pharmatech ABOUT US Company Overview Mission & Vision CEO’s Message D&D Companies Management Contact PIPELINE Overview GLP-1 Therapeutics Other Pipeline Expanded Access Policy R&D R&D Competency Technology Achievements New Business Valted Seq z-alpha Investors & Media IR Information Disclosure Electronic Announcements Press Releases Notices Recruit EN KR EN ABOUT US Company Overview Mission & Vision CEO’s Message D&D Companies Management Contact PIPELINE Overview GLP-1 Therapeutics Other Pipeline Expanded Access Policy R&D R&D Competency Technology Achievements NEW BUSIN
Neuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04 – Boston Harbor Angels Search Home About Us Celebrates 20 Years of Angel Investing Letter to Founders Facts Management Team Internship Program For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner For Founders What Industries? Where Do We Invest? Apply! Schedule Consultation with Z! Boston Harbor Angels Lighthouse What Founders Say! Portfolio Portfolio Store News News Linke … anagement Team Internship Program For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner For Founders What Industries? Where Do We Invest? Apply! Schedule Consultation with Z! Boston Harbor Angels Lighthouse What Founders Say! Portfolio Portfolio Store News News LinkedIn Media Podcast Contact Us Home News Portfolio News Neuraly and Enigma Biomedical USA announce a Research License and Commercia … e About Us Portfolio News Contact For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner Follow Us Facebook Linkedin Copyright © 2023. Boston Harbor Angels. All Rights Reserved. This website is created and maintained by Business IT Essentials Manage Cookie Consent We use cookies to optimize our website and our service. Functional Functional Always active The technical storage or access is
%PDF-1.4 %���� 7062 0 obj > endobj xref 7062 213 0000000016 00000 n 0000007634 00000 n 0000007797 00000 n 0000009758 00000 n 0000009816 00000 n 0000009888 00000 n 0000009941 00000 n 0000009994 00000 n 0000010047 00000 n 0000010099 00000 n 0000010152 00000 n 0000010204 00000 n 0000010255 00000 n 0000010307 00000 n 0000010360 00000 n 0000010413 00000 n 0000010493 00000 n 0000010545 00000 n 0000010597 00000 n 0000010649 00000 n 0000010701 00000 n 0000010753 00000 n 0000010805 00000 n 0000010857 00000 n 0000010908 00000 n 0000010961 00000 n 0000011013 00000 n 0000011065 00000 n 0000011117 00000 n … ���b�6=N-�&�D���r'ڍ���;i����8��q N-�F�H��rG:�N��ńN �&tB't�2������b�. >stream application/pdf FINAL_BSA_December copy 2017-11-21T12:17:47+05:30 2017-11-21T12:17:47+05:30 2017-11-21T12:17:47+06:30 Adobe Illustrator CC 2017 (Windows) uuid:e3ac8f63-f852-40ca-a8fc-77acf3c02e5f xmp.did:de5b7875-596f-c245-a6ca-2f33ae839bf3 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf 1 uuid:a1b5529a-f9e3-42b0-961b-43b0687775f1 xmp.did:b74ca257-9f52-e74e-a39d-4522a5fe678a uuid:5D20892493BFDB119 … 28T12:38:35+05:30 Adobe Illustrator CC 2017 (Windows) 2017-11-28T12:38:35+05:30 application/pdf BSA Subscription Advt copy shridhar Adobe PDF library 15.00 False 1 B 1 True False 21.000000 29.700000 Centimeters NewsGothicStd-Bold News Gothic Std Bold Open Type OTF 1.018;PS 001.001;Core 1.0.31;makeotf.lib1.4.1585 False NewsGothicStd-Bold.otf AkzidenzGrotesk-Bold AkzidenzGrotesk Regular TrueType Version 001.001 False AKZIDENZ-GROTESK-BOLD.TTF ArialMT Arial Regular Open Type Ver … 犥�e ���2� �CX�O{o ��� endstream endobj 82 0 obj > endobj 83 0 obj >stream application/postscript MEDICK16AD_E_Infomedix_H280xW210_4C_0928 Hamada, Mihoko (RX) 2017-11-13T09:56:27+09:00 2017-11-13T09:58:30+09:00 2017-11-13T09:58:30+09:00 Adobe Illustrator CC 2015 (Macintosh) xmp.iid:0ae77b6d-49ae-401e-a12f-33c311283c02 xmp.did:0ae77b6d-49ae-401e-a12f-33c311283c02 uuid:5D20892493BFDB11914A8590D31508C8 default 1 uuid:1e5061c2-458f-1749-b7cd-a17cfd3293ff xmp.did:6d6a8c23-88a … ��%�g��� ��̢bH $Ҥ%?IJ�&M k�e6��ZuK k ��#�3A�!O>�qHI9 ����g|m�s&�D�uGk0��urfPʴkM %T��f�$$�AZ�pcCR��V�=�&!iZ) Β���#��iK��\HB d�#Q�҈��ԍ���$$���h�N�_ll$3\� ���� �f����- �B�@��,td;G�����PE`mI7N˧�>��)�r�Q�i)����dE��BfpN �d��E INK��Z�4��s �F�у�)��&�!�1�(�3�Jq���vx�C�t�L� nR�K{��rF�ln f��-_ �� ���wF�L# #_469�#|���
MET-224 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 20 Jun 2026 MET-224 Last update 20 Jun 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Biosimilar Regulation Overview Basic Info Drug Type Synthetic peptide Synonyms MET-224o, MET224, PF-08656796 Target GLP-1R Action agonists Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) Therapeutic Areas Endocrinology and Metabolic Disease Active Indication Obesity Inactive Indication - Originator Organi … , offering Metsera up to $9bn, which the biotech considered a “superior company proposal”. The lawsuit, filed in the Delaware Court of Chancery, alleges that Novo Nordisk and Metsera breached the contractual merger agreement, claiming “breach of contract, breach of fiduciary duty, and tortious interference”. Pfizer made additional claims against Novo Nordisk in its lawsuit announcement, alleging that the Danish pharma’s acquisition offer of Metsera is an “illegal attempt by a … t position in this segment. Pfizer refuted Metsera’s claims that Novo Nordisk’s proposal was superior, noting that it “cannot qualify as superior” relative to its deal with Metsera under the merger agreement. In Pfizer’s eyes, this is because Novo Nordisk’s transaction is unlikely to be completed due to the regulatory risk associated with it. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. … eaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now Acquisition Phase 1 Phase 2 Clinical Result 12 May 2025 · www.globenewswire.com Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-lon … d disciplined capital deployment. We believe we have sufficient cash on hand to fund operations into 2027.” Pipeline Highlights and Upcoming Milestones MET-097i: Phase 2b program on track, with Phase 3 initiation planned in late 2025 MET-097i is a fully biased, monthly, ultra-long acting, subcutaneously injectable GLP-1 receptor agonist (RA). In
#healthcareresearch #ukhealthcare #rdf26 | The Research and Development Forum LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agr
Startup Neuraly Raises $36M to Bring Potential Disease-Modifying Treatments to Patients with Parkinson’s Disease | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Ophthalmics Collaboration and Licensing Agreements Benchmark Report 2026: Structured Analysis of 374 Deals - Upfronts, Milestones, and Royalty Structures Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,096.30 +48.70 +1.20% ADVERTIS
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Neuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04 | Financial Post Advertisement oop Story continues below This advertisement has not loaded yet, but your article continues below. Skip to Content Challenge your brain with PUZZMO's daily puzzles. Start playing >> Challenge your brain with PUZZMO's daily puzzles. Start playing >> Sections Search Search financialpost.com Perform search Share Share this Story : Financial Post Copy Link Email X Reddit LinkedIn Tumblr Subscribe for $0.99/week User My Account Subscrib
Frontiers | The Disease Modification Conundrum in Parkinson’s Disease: Failures and Hopes Frontiers in Aging Neuroscience About us About us Who we are Mission and values History Leadership Awards Impact and progress Frontiers' impact Our annual reports Thought leadership Publishing model How we publish Open access Quality and research integrity Peer review Research Topics Publish your data Fee policy Services Societies National consortia Institutional partnerships Collaborators More from Frontiers Frontiers Forum Frontiers Planet Prize Press office Sustainability Career opportunities Conta … office Sustainability Career opportunities Contact us All journals All articles Submit your research Search Frontiers in Aging Neuroscience Sections Sections Aging Neuroscience Archive Alzheimer's Disease and Related Dementias Cellular and Molecular Mechanisms of Brain-aging Neurocognitive Aging and Behavior Neuroinflammation and Neuropathy Parkinson’s Disease and Aging-related Movement Disorders Articles Research Topics Editorial board About journal About journal Scope F … rnal sections Open access statement Copyright statement Quality For authors Why submit? Article types Author guidelines Editor guidelines Publishing fees Submission checklist Contact editorial office About us About us Who we are Mission and values History Leadership Awards Impact and progress Frontiers' impact Our annual reports Thought leadership Publishing model How we publish Open access Quality and research integrity Peer review Research Topics Publish your data Fee p … partnerships Collaborators More from Frontiers Frontiers Forum Frontiers Planet Prize Press office Sustainability Career opportunities Contact us All journals All articles Submit your research Frontiers in Aging Neuroscience Sections Sections Aging Neuroscience Archive Alzheimer's Disease and Related Dementias Cellular and Molecular Mechanisms of Brain-aging Neurocognitive Aging and Behavior Neuroinflammation and Neuropathy Parkinson’s Disease and Aging-related Movement D … rnal sections Open access statement Copyright statement Quality For authors Why submit? Article types Author guidelines Editor guidelines Publishing fees Submission checklist Contact editorial office Frontiers in Aging Neuroscience Sections Sections Aging Neuroscience Archive Alzheimer's Disease and Related Dementias Cellular and Molecular Me
ESPN Events’ Fenway Bowl Announces Wasabi Technologies as Title Sponsor – Boston Harbor Angels Search Home About Us Celebrates 20 Years of Angel Investing Letter to Founders Facts Management Team Internship Program For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner For Founders What Industries? Where Do We Invest? Apply! Schedule Consultation with Z! Boston Harbor Angels Lighthouse What Founders Say! Portfolio Portfolio Store News News LinkedIn Media Podcast Contact Us Home About Us Celebrates 20 Years … anagement Team Internship Program For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner For Founders What Industries? Where Do We Invest? Apply! Schedule Consultation with Z! Boston Harbor Angels Lighthouse What Founders Say! Portfolio Portfolio Store News News LinkedIn Media Podcast Contact Us Home News Portfolio News ESPN Events’ Fenway Bowl Announces Wasabi Technologies as Title Sponsor ESP … Nov November 3, 2020 Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease Neuraly, Inc., a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced it has received clearance of... read more 08 Jun June 8, 2018 Emovi’s KneeKG Device Accepted to Smart Health Innovation Lab’s Certification Program, USA Emovi, tod … nd the health centers first secured a two-year Partnership for Community Health grant to create a teledermatology service at... read more 20 Feb February 20, 2018 Thinking pink: KnipBio launches bio-astaxanthin US feed ingredient innovator KnipBio has launched a new line of of its KnipBio Meal product containing bio-astaxanthin, the carotenoid... read more Categories Angel Infographics Angel Tips Blog Member News Organization News Portfolio News Press Release Uncategorized Ar … e About Us Portfolio News Contact For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner Follow Us Facebook Linkedin Copyright © 2023. Boston Harbor Angels. All Rights Reserved. This website is created and maintained by Business IT Essentials Manage Cookie Co
Andrew Eckert – Page 17 – BioHealth Capital Region Home BHCR Forum BHCR Forum 2024 BHCR Forum 2023 BHCR Forum 2022 BHCR Forum 2021 BHCR Forum 2020 BHCR Forum 2019 Investment Conference Contact Press enter to begin your search No menu assigned! All Posts By Andrew Eckert Nov 04 0 BioBuzz: BioHealth Capital Region Showcases Strengths of Cutting Edge Therapies By Andrew Eckert | BioBuzz , News | No Comments Biopharma and Life Science companies in the BioHealth Capital Region are known for their work with cutting edge technologies such as gene and cell therapies. Those strengths were o … via BioBuzz Nov 02 0 Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease By Andrew Eckert | News | No Comments GAITHERSBURG, Md.–( BUSINESS WIRE )– Neuraly, Inc. , a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced it has received clearance of an investigational new drug application (IND) to initiate … employers, such as Phlow Corporation (recent recipient of a $354 million BARDA grant to domestically produce certain API’s), Kaleo, FUJIFILM Wako Chemicals, and GlaxoSmithKlein Consumer Healthcare. The Charlottesville area has an industry cluster of 179 firms and organizations in biotech and medical devices related industries that employ 3,033 workers, many with connection to the University of Virginia. Over the past 10 years, the region has seen nine major exits from compan … res, PhD, RAC, Associate, Wilson Sonsini Goodrich, Rosati Andrea Alms, MS, MBA, Fund Manager, BioHealth Capital Fund. Rich Bendis, President & CEO, BioHealth Innovation, Inc. moderated the event and stated “The judges made clear this was a particularly competitive group of finalists. We congratulate all the presenters on their progress to date and wish them great success in the future.” BrainScope joins a group of prior winners all of whom have advanced their technologies
Access Denied Access Denied You don't have permission to access "http://www.businesswire.com/AK_PM_VPATH1/714432/bw_maintenance.html" on this server. Reference #18.11c41402.1782542566.183f387b https://errors.edgesuite.net/18.11c41402.1782542566.183f387b
Neuraly, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Neuraly, Inc. Startups | Holding Company | 2016 | Maryland, United States | 50-100 | www.neuralymed.com Startups | Holding Company | 2016 | Maryland, United States | 50-100 | www.neuralymed.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Endocrinology and Metabolic Disease Nervous System Diseases Digestive System Disorders Synthetic peptide Small molecule … Intellectual Property Administration, PRC (CNIPA) had issued a notification to grant a patent for the intrathecal administration of the company's cellular therapies in patients with multiple sclerosis (MS). The intrathecal administration is an established method used to deliver therapy across the blood-brain barrier via injection into the subarachnoid space. In June 2024, Orca Bio announced that it had completed enrollment in the pivotal Precision-T Phase III clinical study. … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Neuraly Directory – Maryland Tech Council Skip to content Maryland Tech Council ABOUT About MTC Board Team Contact Terms, Conditions and Policies. MEMBERSHIP Join Benefits Driving Value to Our Members Savings & Rewards Program B2B Connections Mentorship at MTC Directory Online Community Member News Member Blog NETWORKS Rural Technology Network Regional Networks ADVOCACY Priorities Data Center Alliance of Maryland Bills of Interest Protecting Innovation Get Involved CONFERENCES Bio Innovation Conference Maryland Data Center Summit Technology Transformation Conference EVENTS Events Ca
Seulki Lee - Founder and CEO at Neuraly | The Org Platform Enrich Pricing Log in Sign up Neuraly Seulki Lee Unverified Seulki Lee Founder and CEO Contact Seulki Lee has extensive work experience in the biotech and pharmaceutical industry. Seulki is the Founder and CEO of D&D Pharmatech, a clinical-stage global biotech company focused on developing revolutionary medicines. In 2016, they also founded Neuraly, Inc., a clinical-stage company that translates neurology scientific discoveries into new drugs for neurodegenerative disorders. Seulki Lee is currently the CEO of Precision Molecular,
D&D raises $137M to fund inflammation tech out of JHU : 네이버 블로그 본문 바로가기 블로그 카테고리 이동 바ㅣㅗ세상 검색 MY메뉴 열기 바이오뉴스(국내) D&D raises $137M to fund inflammation tech out of JHU 봐요세상 2019. 8. 17. 21:40 이웃추가 본문 기타 기능 본문 폰트 크기 조정 본문 폰트 크기 작게 보기 본문 폰트 크기 크게 보기 가 공유하기 URL복사 신고하기 7:51 AM KST | AUG 15, 2019 | BC EXTRA | FINANCIAL NEWS BY ELIZABETH S. EATON, STAFF WRITER South Korea’s D&D Pharmatech raised $137.1 million in a series B round to push forward the pipelines of its trio of inflammation-focused subsidiaries. Founded in 2014, D&D Pharmatech Co. Ltd. (Gyeonggi-do, South Korea) is the pare … round last year, was created by Ted Dawson in 2016. The series B is expected to fund Phase II trials of lead candidate NLY01, a GLP-1R agonist, in Parkinson's disease and Alzheimer's disease starting in 2019 and 2020, respectively. Dawson is the director of the Institute for Cell Engineering at Johns Hopkins School of Medicine (see "Neuraly Debuts with $36M" ). Precision Molecula r was launched this year by Martin Pomper, director of the Division of Nuclea … eceptor superfamily member 10b {"title":"D&D raises $137M to fund inflammation tech out of JHU","source":"https://blog.naver.com/yplee0321/221619687320","blogName":"바ㅣㅗ세상","domainIdOrBlogId":"yplee0321","nicknameOrBlogId":"봐요세상","logNo":221619687320,"smartEditorVersion":4,"meDisplay":true,"lineDisplay":true,"outsideDisplay":
Neuraly Advances NLY01 MS Phase 2 Trial | cGxP.wire posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s Use
Neuraly, 1st Biotherapeutics take aim at Parkinson's with brain penetrant c-Abl inhibitors + | Bioworld | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review … ors for Parkinson's disease with aims to file an investigational new drug (IND) application with the FDA next year. BioWorld Asia Popular Stories Today's news in brief BioWorld BioWorld briefs for June 26, 2026. Have brain-computer interfaces finally arrived? BioWorld More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural... News in brief BioWorld Asia BioWorld Asia briefs fo
PEGS Boston Summit 2026 Participant List About About the Event FAQ Social Media Wall Get Involved Attendee List Media Gallery Testimonials Archives Agenda Search Agenda Conference Programs Training Seminars Short Courses Plenary Keynote Sessions Top Pharma Presentations Interactive Discussions Speaker Biographies Networking Events Connect & Share with Your Network Sponsor/Exhibitor Attendee Demographics + Event Features Sponsorship Opportunities Current Sponsors Current Exhibitors / Floorplan 27 Re-sign Floorplan Sponsor/Exhibitor Prospectus Exhibit Services/Schedule Lead Generation Opport
Licensing Deals in Biotechnology 2020-2026 - Research and Markets Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscription … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … Forecasts, Till 2035 - Distribution by Source of Cell Line / Expression System, Application of Cell Line, Company Size, and Key Geographical Regions  Report 455 Pages December 2025 Global From €4311 EUR $4,799 USD £3,730 GBP This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user … ng Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
Arkivum RDF24 Log in Language Organizing events? Resource center Contact app support Legal Home Speakers Exhibitors Agenda Arkivum Exhibition Stand · Arkivum Bookmark Information Arkivum offers a digital archiving and preservation solution that caters to the long-term retention, compliance, and access needs of life sciences, pharmaceutical and healthcare organisations. Our customer base includes the NHS, Neuraly, Cerevel Therapeutics, Aspire Pharma, University of Nottingham and more. Our cost-effective solution is aligned to industry best practice approaches for long-term data management, incl
Neuraly | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Neuraly Neuraly is a clinical-stage biotechnology company dedicated to developing revolutionary treatments for neurodegenerative diseases such as Parkinson’s and Alzheimer’s. The company focuses on addressing new pathways and leveraging innovative science to create disease-modifying therapies that can change lives. With a strong scientific platform and a talented team, Neuraly aims to be a leader in discovering and developing breakthrough medicines. Industries biotechn
DRSLTR 1 filename1.htm DRSLTR 200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh Dubai San Diego December 11, 2024 Düsseldorf San Francisco Frankfurt … ongoing Phase 1/2 trials, revise to explain when companies typically make a BLA application (e.g., following successful completion of all required clinical trials and at same time the company seeks marketing approval). Response: In response to the Staff’s comment, the Company has revised the disclosure on pages 1, 2, 124, and 146 of Amendment No. 1. 2. We note your disclosure that you are advancing a “broad, scalable and combinable portfolio of injectabl … pound MET-002, a predecessor peptide to MET-224o, following your Clinical Trial Application being approved by Health Canada in October 2024. We also note your disclosure on page 25 stating that you and your collaborators are “currently conducting” clinical trials in foreign countries. Response: In response to the Staff’s comment, the Company has revised the disclosure on pages 1, 2, 7, 123, 124, 129, 132, 154, 155, 158, and 162 of Amendment No. 1. The Obes
Pipeline — Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Pipeline NLY01 Drug Candidate NLY01 Summary First-in-Class GLP-1R agonist for Neurodegenerative Disease Mechanism of Action Long-acting, microglia-targeted GLP-1R agonist Indication Parkinson’s Disease (NLY01-PD) Alzheimer’s Disease (NLY01-AD) Development Stage Phase II Description NLY01 is a pegylated exendin-4 analogue of Glucagon Like Peptide-1 Rece
%PDF-1.7 %���� 1 0 obj >stream VoR 10.1002/mdc3.13360 10.1002/mdc3.13360 10.1002/(ISSN)2330-1619 3 Demographic Influences on the Relationship Between Fatigue and Quality of Life in Parkinson's Disease Acrobat Distiller 11.0 (Windows); modified using iText 4.2.0 by 1T3XT 2021-10-28T09:38:01-07:00 endstream endobj 4 0 obj >stream hޜ[[s��r�T��+��*����\�V ��� ��Ҧ*e�"! �$�H����C�w�_� .��\e��`.�_}��/��{������L�.o��|��?�c�E�S7˔Y�:5���35[�l�Pz��j���tv��ϒ���Yu�/{��"MS%��8�ϋ��[hM�\� �h���ܯ+�pF3z}���9�\�C�`���K�Q{��SryW=�[�-����V��iќ/�dwWwr��r[� ;����$�fKw�j%o57�X,lRʠ>���]��cMc ����R� … 4+LIYwyCz0+ys04WsCQr34AAn5
nqc2+LBDGKgAGYFK+WpdirsVdirsVdirsVdirsVdir//2Q== application/postscript saved xmp.iid:40338E756D63E411A01CE06922E7E506 2014-11-05T17:29:33+05:30 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:6915BBD94C60E611AD72B662A92B5C94 2016-08-12T10:53:06+05:30 Adobe Illustrator CS6 (Windows) / converted from applicat … 5:30 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:3548084a-5e0c-d64a-b180-1776fcb21313 2017-01-09T12:47:32+05:30 Adobe Illustrator CC 2014 (Windows) / saved xmp.iid:bc1ba4e7-2a58-734c-a255-c04fb17861f2 2017-01-09T12:47:36+05:30 Adobe Illustrator CC 2014 (Windows) / xmp.iid:3548084a-5e0c-d64a-b180-1776fcb21313 xmp.did:3548084a-5e0c-d64a-b180-1776fcb21313 uuid:645c43a3-feca-4153-b60b-9a2a9dfc6428 uuid … 4+LIYwyCz0+ys04WsCQr34AAn5
nqc2+LBDGKgAGYFK+WpdirsVdirsVdirsVdirsVdir//2Q== application/postscript saved xmp.iid:40338E756D63E411A01CE06922E7E506 2014-11-05T17:29:33+05:30 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:6915BBD94C60E611AD72B662A92B5C94 2016-08-12T10:53:06+05:30 Adobe Illustrator CS6 (Windows) / converted from applicat … 5:30 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:3548084a-5e0c-d64a-b180-1776fcb21313 2017-01-09T12:47:32+05:30 Adobe Illustrator CC 2014 (Windows) / saved xmp.iid:bc1ba4e7-2a58-734c-a255-c04fb17861f2 2017-01-09T12:47:36+05:30 Adobe Illustrator CC 2014 (Windows) / xmp.
Accelerate GLP-1/GCG cyclic peptide conjugate drug to IND Skip to content About Us Facilities Leadership Environmental, Social & Governance Services & Solutions Oligonucleotide Overview Peptide Overview Catalog Product Oligonucleotide Overview Discovery Synthesis Oligonucleotide Conjugate Monomer & Ligand Development & Manufacturing API Drug Product Analytical Regulatory Dossier Preparation Peptide Overview Discovery Synthesis Peptide Conjugate Unnatural Amino Acid Development & Manufacturing API Drug Product Analytical Regulatory Dossier Preparation Catalog Product News & Resou … tion you provided for our internal use, in accordance with our Privacy Policy . Submit Close GDPR Cookie Settings Privacy Overview Strictly Necessary Cookies Powered by GDPR Cookie Compliance Privacy Overview This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections
Science — Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Science Activation of glial cells in neural tissue plays a critical role in pathogenesis of neurodegenerative diseases. To date, there are no disease-modifying therapies that reverse, stop or slow the relentless neurodegeneration in Parkinson’s (PD), Alzheimer’s (AD) and other neurodegenerative diseases. The existing treatments only provide temporary symptomat
Attendee List | Immunogenicity & Bioassay Summit | October 19-22, 2026 About About the Event FAQ Attendee List Key Contacts Media Gallery Testimonials Agenda Programs Short Courses Symposium Training Seminars FDA Presentations Interactive Discussions Speaker Biographies Archives Sponsor/Exhibitor Attendee Demographics + Event Features Sponsorship & Exhibitor Opportunities Current Sponsors Exhibitor Prospectus Exhibitor Kit Floorplan Lead Generation Opportunities Downloads Brochure Downloads Articles Travel Posters Poster Information Poster Titles Media Media Partners Press Passes Regis
Enigma Biomedical & Neuraly Announce Research & Commercialization Deal Moe Alsumidaie Chief Editor Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation. Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Cell and Gene Therapy Clinical AI Clinical Decision Support Clinical Operations Clinical Research Clinical Tri … Brain Health in Cognitive Decline --> Previous post Nasdaq Lists Disc Medicine Grant Under Rule 5635(c)(4) Next post Acalabrutinib Plus Chemoimmunotherapy Approved for Mantle Cell Lymphoma Leave a Comment Cancel reply You must be logged in to post a comment. You Might Also Like News US Oncology Network Grows in Tennessee with New Partnership August 8, 2024 News Taysha Gene Therapies Announces Inducement Grant January 6, 2025 News Kalaris Launches Promising New Trial for Macu
Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact We discover and develop revolutionary treatments for neurodegenerative diseases We’re in the business of offering new hope. Neuraly was founded to develop new drugs that change our expectations about successful treatment of progressive diseases like Alzheimer’s and Parkinson’s. We are developing drugs that address new pathways, capitalize on our founder’s innovation, and deliver med
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
The IX Cedars-Sinai Parkinson's Disease and Movement Disorders Annual Symposium - Cedars-Sinai - Continuing Education (CE) Gastroenterology</Profession><Profession>Internal Medicine</Profession><Profession>Nuclear Medicine</Profession><Profession>Neurology</Profession><Profession>Physical Medicine &amp; Rehabilitation</Profession><Profession>Family / General Medicine</Profession><Profession>Geriatrics</Profession><Profession>Neurosurgery</Profession><Profession>Psychiatry</Profession" /> Cedars-Sinai faculty members who have transitioned t … Your Password ?" link. Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … y appreciate support received from the Edward H. Davis, MD Memorial Lectureship Fund. Acknowledgement of Commercial Support Cedars-Sinai gratefully acknowledges educational grants from Boston Scientific and Medtronic. Credits AMA PRA Category 1 Credit(s)™ (MD, DO) (7.00 hours), Non-Physician AMA Attendance (7.00 hours) Keywords: LIVE AMA IMPORTANT ANNOUCEMENT We are currently experiencing issues with user’s account names, disclosure, and transcripts. We are actively wo … r Package - Exhibit fee Price: $2500.00 Includes: Number of Exhibitor Badges: 2 Deadline for order commitment is 10/18/2023 12:00:00 AM. CE Disclosure Form | CE Application | Privacy | Cedars-Sinai CME Homepage Contact Us: [email protected] © 2026 Cedars-Sinai Health Sciences University. All Rights Reserved. A 501(c)(3) non-profit organization.
%PDF-1.4 %���� 376 0 obj > endobj xref 376 77 0000000016 00000 n 0000002768 00000 n 0000002930 00000 n 0000003813 00000 n 0000004164 00000 n 0000004596 00000 n 0000004710 00000 n 0000005060 00000 n 0000005186 00000 n 0000007370 00000 n 0000007994 00000 n 0000008579 00000 n 0000009222 00000 n 0000011113 00000 n 0000016734 00000 n 0000016848 00000 n 0000052674 00000 n 0000052713 00000 n 0000088539 00000 n 0000088578 00000 n 0000125049 00000 n 0000125088 00000 n 0000125166 00000 n 0000125528 00000 n 0000125849 00000 n 0000126276 00000 n 0000126354 00000 n 0000126730 00000 n 0000126808 00000 n 000 … ����U�r��~�+y/��\K-,�/ϑ�˛�U2M�p�h�A ����?���p�*� > endobj 391 0 obj >stream application/pdf polygon 2015-11-23T09:49:47-05:00 2015-11-23T09:49:47-05:00 2015-11-23T09:49:47-05:00 Adobe Illustrator CC 2014 (Macintosh) uuid:3e9a76b5-3665-644f-b793-07211f88198a xmp.did:ddfde353-a810-4434-9d95-b501e93fc7fb uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:d1c078a0-2746-42b2-b0d1-25aedff8fb1e xmp.did:1b6690ed-28a8-c141-9479-b6a9cf6be651 uuid:5D20892493BFDB11914A8590D31508C8 … 0 Adobe PDF library 11.00 endstream endobj 392 0 obj > endobj 393 0 obj >stream application/pdf polygon 2015-11-23T09:49:47-05:00 2015-11-23T09:49:47-05:00 2015-11-23T09:49:47-05:00 Adobe Illustrator CC 2014 (Macintosh) uuid:3e9a76b5-3665-644f-b793-07211f88198a xmp.did:ddfde353-a810-4434-9d95-b501e93fc7fb uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:d1c078a0-2746-42b2-b0d1-25aedff8fb1e xmp.did:1b6690ed-28a8-c141-9479-b6a9cf6be651 uuid:5D20892493BFDB11914A8590D31508C8 … 0 Adobe PDF library 11.00 endstream endobj 394 0 obj > endobj 395 0 obj >stream application/pdf CEN_MediaGroup_Whitepapers_redNEW 2021-02-11T09:53:05-05:00 2021-02-11T09:53:05-05:00 2021-02-11T09:53:04-05:00 Adobe Illustrator 24.1 (Macintosh) uuid:f5a067a2-7103-9343-87a4-96ac9aea13ce xmp.did:40e2cd7e-0726-4e17-9290-c3e3a9d61c77 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:385365d9-770b-8344-9325-2c1ecbd39212 xmp.did:457905d4-24fb-4cf3-9a04-d5239c5c1c45 uuid:5D20892493 … �,8r%��/Aw�D��B�1 �� �DZEp ����,�F;� ��~ endstream endobj 41 0 obj >stream application/pdf polygon 2015-11-23T09:49:47-05:00 2015-11-23T09:49:47-05:00 2015-11-23T09:49:47-05:00 Adobe Illustrator CC 2014 (Macintosh) uuid:3e9a76b5-3665-644f-b793-07211f88198a xmp.did:ddfde353-a810-4434-9d95-b501e93fc7fb uuid:5D20892493BFDB11914A8590D31508C8 pro
NLY01| ACNR HOME ISSUES EXPLORE CONTENT Introduction Articles Book Reviews Case Reports News Sponsored Editorials EVENTS Introduction Event News Conference Reports Submit your Course or Conference AUTHORS Introduction ACNR Author Guidelines Author Disclosure RESOURCES ABOUT Introduction How is ACNR Funded? Editorial Board Peer Reviewers ACNR Policies and Forms Ethics and Malpractice Email Newsletter Journal Signup ACNR Privacy Policy This website is intended for healthcare professionals Ad Area --> HOME ISSUES EXPLORE CONTENT Introduction Articles View All Articles Reviews Personal Perspective … r Series Sponsored Editorials EVENTS Introduction Event News Conference Reports Submit your Course or Conference AUTHORS Introduction ACNR Author Guidelines Author Disclosure RESOURCES ABOUT Introduction How is ACNR Funded? Editorial Board Peer Reviewers ACNR Policies and Forms Ethics and Malpractice Email Newsletter ACNR Online Community Signup ACNR Privacy Policy --> Menu Phase 2 Trial of NLY01 in Parkinson’s Disease: Topline results Posted on 28 March, 2023 - Parkins … thday Honours for Huntington’s disease research Choose Neurology Teva files FDA application for ecopipam in paediatric Tourette syndrome MS relapses remain rare after age 60 whether DMTs are continued or stopped Peppermint oil shows potential to lower blood pressure in new study Tourettes Action launches #NoChoice campaign to challenge misconceptions about Tourette syndrome AbbVie’s AQUIPTA® (atogepant) is recommended by NICE as an option for the acute treatment of migraine i
Access Denied Access Denied You don't have permission to access "http://www.businesswire.com/AK_PM_VPATH1/714432/bw_maintenance.html" on this server. Reference #18.d0a0d517.1782540901.6ba3ce81 https://errors.edgesuite.net/18.d0a0d517.1782540901.6ba3ce81
November 2020 – Page 2 – BioHealth Capital Region Home BHCR Forum BHCR Forum 2024 BHCR Forum 2023 BHCR Forum 2022 BHCR Forum 2021 BHCR Forum 2020 BHCR Forum 2019 Investment Conference Contact Press enter to begin your search No menu assigned! Monthly Archives November 2020 Nov 04 0 BioBuzz: BioHealth Capital Region Showcases Strengths of Cutting Edge Therapies By Andrew Eckert | BioBuzz , News | No Comments Biopharma and Life Science companies in the BioHealth Capital Region are known for their work with cutting edge technologies such as gene and cell therapies. Those strengths wer … via BioBuzz Nov 02 0 Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease By Andrew Eckert | News | No Comments GAITHERSBURG, Md.–( BUSINESS WIRE )– Neuraly, Inc. , a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced it has received clearance of an investigational new drug application (IND) to initiate
Neuraly - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Com … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Neuraly NEWS JOBS NEWS Drug Development Startup Neuraly Launches with $36 Million: Targets Neurodegenerative Diseases Maryland-based Neuraly surged forth from the startup gate with $36 million in Series A funding that will finance the company’s research into the development of therapies for neurodegenerative disorders. July 18, 2018 … ead Drug Development Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease November 2, 2020 · 3 min read Drug Development CORRECTING and REPLACING Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease March 3, 2020 · 4 min read Deals D&D Pharmatech Raises $137.1M in Series B Financing to Advan … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Neuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04 January 17, 2025 | 4 min read Twitter LinkedIn Facebook Email Print KNOXVILLE, Tenn.--(BUSINESS WIRE)--On January 16, 2025, Neuraly Inc. (Neuraly), a wholly owned subsidiar … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Neuraly Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 2B Trial of NLY01 for Patients with Alzheimer’s Disease November 2, 2020 | 3 min read Twitter LinkedIn Facebook Email Print Novel Mechanism of Action Inhibits Pathological Activation of Microglial … rders, today announced it has received clearance of an investigational new drug application (IND) to initiate a Phase 2B trial of NLY01 in patients with Alzheimer’s disease. NLY01 is also being evaluated in patients with Parkinson’s disease in a Phase 2 trial initiated in February 2020. “Initiation of this Phase 2 study in Alzheimer’s disease represents an important milestone in the ongoing advancement of NLY01,” said Seulki Lee, Ph.D., President and Chief Executive Officer o … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Startup Neuraly Raises $36M to Bring Potential Disease-Modifying Treatments to Patients with Parkinson’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital Startup Neuraly Raises $36M to Bring Potential Disease-Modifying Treatments to Patients with Parkinson’s Disease July 18, 2018 | 3 min read Twitter LinkedIn Facebook Email Print Research published in Nature Medicine demonstrates protection against dopamine loss and behavioral deficits associated with Parkinso … Bio&Pharma. Two U.S.-based funds, Octave Life Sciences and Maryland Venture Fund, also participated in this financing. In turn, the following representatives will join Seulki Lee, Ph.D., Chairman and Founder, and Viktor Roschke, Ph.D., Co-founder on the Board of Directors: John Ku, Executive Vice President of Smilegate Investment, Phillip Jung, Associate at Maryland Venture Fund, Junghee Lim, Executive Managing Director of InterVest and Keele Park, CEO of Magna Investment … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuraly Announces Strategic Sponsored Research Agreement with the University of Pennsylvania to Explore use of NLY01 to Therapeutically Target a Neuroinflammatory Mechanism of Glaucoma - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Sh … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital Neuraly Announces Strategic Sponsored Research Agreement with the University of Pennsylvania to Explore use of NLY01 to Therapeutically Target a Neuroinflammatory Mechanism of Glaucoma November 10, 2020 | 4 min read Twitter LinkedIn Facebook Email Print Study recently published by Penn team in Cell Reports pr … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
1ST Bio and Neuraly Collaborate to Advance Novel c-Abl Inhibitors for Parkinson's Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business 1ST Bio and Neuraly Collaborate to Advance Novel c-Abl Inhibitors for Parkinson’s Disease October 25, 2017 | 3 min read Twitter LinkedIn Facebook Email Print 1ST Bio today announced a collaboration to co-develop novel brain penetrant c-Abl inhibitors for Parkinson’s disease. [25-Octobe … clinical models of the disease. The goal is to file an Investigational New Drug application with the FDA next year. 1ST Biotherapeutics will retain all intellectual property generated in the collaboration. Financial and other terms were not disclosed. About Neuraly, Inc. Neuraly is a private biotech company that is developing therapeutics for neurodegenerative diseases, including Parkinson's and Alzheimer's diseases. Neuraly is a startup from Johns Hopkins University. For mor … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
News & Articles | BioBuzz All Regions All Regions BioHealth Capital Region Greater Philadelphia Research Triangle Park News Events BioCatalyst Program Sign Up News & Articles The latest in life sciences from across BioBuzz’s regional hubs. All Regions All Regions BioHealth Capital Region 2249 Boston-Cambridge 1 Greater Philadelphia 611 Maryland 8 North Carolina 3 Research Triangle Park 1113 Topics Career & Professional Development 228 Events 107 Funding 218 Industry Trends 1296 Manufacturing 151 People 718 Policy 82 Real Estate 201 Research 334 Workforce 148 Type 5 Questions … Showing 0 of 0 results Funding Press Release OTraces Awarded $2 Million Florida Grant to Advance Non‐Invasive, High‐Accuracy Prostate Cancer Detection June 26, 2026 People 5 Questions With 5 Questions With Chidiebube Chikezie June 25, 2026 Press Release Minaris Enhances GMP Cell Banking Capabilities at Philadelphia Facility June 24, 2026 BioHealth Capital Region Events Why the Future of Cell Therapy Relies on Both Capability and Capacity June 24, 2026 BioHealth Capital Region
D&D Pharmatech 본문 바로가기(Skip Contents) D&D Pharmatech ABOUT US Company Overview Mission & Vision CEO’s Message D&D Companies Management Contact PIPELINE Overview GLP-1 Therapeutics Other Pipeline Expanded Access Policy R&D R&D Competency Technology Achievements New Business Valted Seq z-alpha Investors & Media IR Information Disclosure Electronic Announcements Press Releases Notices Recruit EN KR EN ABOUT US Company Overview Mission & Vision CEO’s Message D&D Companies Management Contact PIPELINE Overview GLP-1 Therapeutics Other Pipeline Expanded Access Policy R&D R&D Competency Technology Ach
%PDF-1.6 %���� 4635 0 obj > endobj 4653 0 obj >/Filter/FlateDecode/ID[ ]/Index[4635 29]/Info 4634 0 R/Length 89/Prev 4013477/Root 4636 0 R/Size 4664/Type/XRef/W[1 2 1]>>stream h�bbd``b`I�;�??�`�"& �X!"^�-��!��"L@�R ��dJ=Ȕx�D/�� ���(� �b``$������F} 4 endstream endobj startxref 0 %%EOF 4663 0 obj >stream h�b```e``Z"��2�0 �P�����#�"O�"�G"g��F�Th�D��C%�] 1s\Y���iu���^Fη ���C�:��"��| [��Lq,�j:��E(�$t��lG��l.�A*��R >/Metadata 277 0 R/PageLabels 4626 0 R/Pages 4629 0 R/StructTreeRoot 540 0 R/Type/Catalog/ViewerPreferences >>> endobj 4637 0 obj >/PageTransformationMatrixList … ��2�Cn���١P�6�OQl�huEH��?XT !�����ӹ|(� "�"���t>��|:Q����9������i��wԠ4 >stream application/pdf Print 2019-10-02T14:13:46-04:00 2019-10-02T14:13:46-04:00 2019-10-02T14:12:36-04:00 Adobe Illustrator CC 23.0 (Windows) uuid:888967c3-18a0-4faf-98d1-da45c673b2c4 xmp.did:4da7ce94-621c-ad4c-8337-7efc5fa1d3a9 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:d1c078a0-2746-42b2-b0d1-25aedff8fb1e xmp.did:1b6690ed-28a8-c141-9479-b6a9cf6be651 uuid:5D20892493BFDB11914A8590D31508C8 proo … ���)�J�0+�ىc �Bé8��F �Q������o������ ��+ endstream endobj 72 0 obj >stream application/pdf Print 2019-10-02T14:13:46-04:00 2019-10-02T14:13:46-04:00 2019-10-02T14:12:36-04:00 Adobe Illustrator CC 23.0 (Windows) uuid:888967c3-18a0-4faf-98d1-da45c673b2c4 xmp.did:4da7ce94-621c-ad4c-8337-7efc5fa1d3a9 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:d1c078a0-2746-42b2-b0d1-25aedff8fb1e xmp.did:1b6690ed-28a8-c141-9479-b6a9cf6be651 uuid:5D20892493BFDB11914A8590D31508C8 proo … 9�4�$SW�ܸ��� �G��.� rRS�S���|�z�Z ��K endstream endobj 94 0 obj >stream application/postscript PF_LIR_logo_color Mark Slattery Adobe Illustrator CC 23.0 (Macintosh) 2019-07-10T16:24:34-04:00 2019-07-10T16:24:34-04:00 2019-07-10T16:24:34-04:00 uuid:9E3E5C9A8C81DB118734DB58FDDE4BA7 xmp.did:a75c2d5b-a5eb-443a-9f5b-3ed67f072c89 xmp.iid:a75c2d5b-a5eb-443a-9f5b-3ed67f072c89 proof:pdf uuid:e36e3c99-dc77-154b-909e-9e9707f70bc4 xmp.did:96e2ad0c-3a62-42c0-9419-8c26c213b295 uuid … �*:�*�y��p>�gc�� �,U�ŃIN{U:��R���ii��6�5 � ��IRv�ՒY�2TOaC\�[.�.�Fډx�Z�$H�rfp�C� �����K+s5�컚�z�Te�4$� A��J�d�;Þ�]R������ks{��4}N�J:��-𧵬�H-;I]�����i� { n f�(:��k������ڑ��,\ �XѲ�7Ң�[姐Л��e��K�ԍ�mǀ���nJ�%q��ZFx�Tr�N�f�n�y�[51#���q�D�{v� � h���� ��J5rQ��3���uiQd> a�9�1�Um�����(��X�t�g��45� %��GT٥Wik)�I�U��m�)�r�P�������fu5�a��F
%PDF-1.5 %���� 457 0 obj > endobj xref 457 33 0000000016 00000 n 0000002126 00000 n 0000002240 00000 n 0000003323 00000 n 0000003519 00000 n 0000003744 00000 n 0000004125 00000 n 0000004162 00000 n 0000004209 00000 n 0000004323 00000 n 0000016075 00000 n 0000027024 00000 n 0000038182 00000 n 0000049541 00000 n 0000061097 00000 n 0000072200 00000 n 0000082657 00000 n 0000093147 00000 n 0000095797 00000 n 0000095893 00000 n 0000095998 00000 n 0000096803 00000 n 0000097113 00000 n 0000102727 00000 n 0000103008 00000 n 0000109962 00000 n 0000110247 00000 n 0000150885 00000 n 0000150924 00000 n 000 … _�qJ�~����Uդ���H�E;k�a0�E��Q��D��g¿?єH2��f�n�� > endobj 483 0 obj >stream application/pdf Cover page 2019-08-16T10:44:59-04:00 2019-08-16T10:44:59-04:00 2019-08-16T10:44:59-04:00 Adobe Illustrator CC 23.0 (Macintosh) uuid:82b29a1e-b39c-4f40-8d51-cbc82e92fe32 xmp.did:c8656e24-68fe-416b-b11c-2696fe7068ed uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:0c4862e3-9ed5-48d4-b548-ae55e15ba542 xmp.did:0c4862e3-9ed5-48d4-b548-ae55e15ba542 uuid:5D20892493BFDB11914A8590D31 … Z(9O�T���� !_�_jIr�J�3g��H�P� '��ሖ�8 �ɩ#I�KY9�� �&�Dh�@ �M�ɄR�%r >stream application/pdf ash.infographs.awardsoverview.doublepie.edit1 2019-08-19T12:02:34-04:00 2019-08-19T12:02:34-04:00 2019-08-19T12:02:34-04:00 Adobe Illustrator CC 23.0 (Windows) uuid:8fdc2a2b-e453-4c28-b070-e44ce2938181 xmp.did:4cb87e7e-b8d6-bd41-a396-d50dfe33144c uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:4dcba6d6-46eb-4a1b-bfbd-e266aa5b696a xmp.did:c103370b-3c9f-d845-afca-c189057357db uu … ���ލL .�YS�\\��0A5� endstream endobj 106 0 obj > endobj 107 0 obj >stream application/pdf ash.infographs.techclass.edit 2019-08-20T10:25:31-04:00 2019-08-20T10:25:31-04:00 2019-08-20T10:25:31-04:00 Adobe Illustrator CC 23.0 (Windows) uuid:cf3f0286-cdff-4a75-aa90-155170e457bd xmp.did:7600446c-eebd-4343-877f-2c2b194781b4 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:8eccb991-621f-d146-a351-9d208ad7d963 xmp.did:c2af4c46-c6e8-4144-b8ce-6bce998ff723 uuid:5D20892493BFD … 0 Adobe PDF library 15.00 endstream endobj 108 0 obj > endobj 109 0 obj >stream application/pdf followon.funding.edit Adobe Illustrator CC 23.0 (Windows) 2019-08-20T10:25:03-04:00 2019-08-20T10:25:03-04:00 2019-08-20T10:25:03-04:00 uuid:9E3E5C9A8C81DB118734DB58FDDE4BA7 xmp.did:013ad672-331c-594e-8698-936efc15a632 uuid:6f7e109d-1ee6-4367-9c5f-8641
Science — Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Science Activation of glial cells in neural tissue plays a critical role in pathogenesis of neurodegenerative diseases. To date, there are no disease-modifying therapies that reverse, stop or slow the relentless neurodegeneration in Parkinson’s (PD), Alzheimer’s (AD) and other neurodegenerative diseases. The existing treatments only provide temporary symptomat
10-Q --12-31 0002040807 false Q1 http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember One http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 0.425 0002040807 us-gaap:SubsequentEventMember mtsr:ZihippLtdMember 2025-04-01 2025-04-30 0002040807 mtsr:DevelopmentMilestoneMember srt:MinimumMember 2024-12-31 0002040807 us-gaap:IndemnificationGuaranteeMember 2025-01-01 2025-03-31 0002040807 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0002040807 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth companyR … arch programs; • the timing of our planned Investigational New Drug (IND) application submissions to the U.S. Food and Drug Administration (FDA) or any comparable submissions to foreign regulatory authorities for our product candidates; • the timing of announcement of interim, topline and preliminary results from clinical trials; • our projected operating expenses and capital expenditure requirements; • our ability to leverage the clinical, regulatory, … es currently in development. Substantial additional financing will be needed to fund our operations and to commercially develop our product candidates, if approved. No assurance can be given that any such financing will be available when needed or that our research and development efforts will be successful. Since our inception in June 2022, we have funded our operations through the issuance of shares of our redeemable convertible preferred stock, convertible notes in private … he available cash and cash equivalents as of March 31, 2025 , will enable us to fund our operating expense and capital expenditure requirements through at least 12 months from the issuance date of these financial statements. 2. Basis of Presentation and Significant Accounting Policies Basis of Presentation Our unaudited condensed consolidated fin
Privacy Policy 1 — Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Privacy Policy Neuraly (collectively, “ COMPANY ,” “ us ,” “ we ,” or “ our ”), has prepared this Privacy Policy (“ Privacy Policy ”) to describe to you, or if you represent an entity or other organization, that entity or organization (in either case, “ you ”) our practices regarding the personal information that COMPANY collects, uses, and shares on behalf … mation You Provide . COMPANY collects personal information when you voluntarily submit it to us. · Personal Information that is Automatically Collected . In addition to personal information that we may receive directly from you, COMPANY indirectly collects other information from you automatically log information about you, your computer or mobile device, and your activity over time on our Website, and other sites and online services. ·  … at . The Website may provide you with the opportunity to chat. If you decide to submit personal information through chat, such personal information may be made available to other Users. 3.7. Referrals . Users may recommend other Users to join the Website by providing their contact information or selecting friends from a social networking site. Users may also provide personal information about other Users of the Website such as reviews of the services or products that he … . If you are a California resident and would like a copy of this notice, please submit your request to the address listed in the section titled “CONTACTING US” below. 7. OTHER SITES AND SERVICES The Website may contain links to other websites and online services operated by third parties. These links are not an endorsement of, or representation that we are affiliated with, any third party. In addition, our content may be included on web pages or online
Contact — Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Contact 704 Quince Orchard Rd, Suite 320 Gaithersburg, MD 20878 240-937-5880 [email protected] Privacy Policy © Copyright 2023, Neuraly Inc 704 Quince Orchard Road #320 Gaithersburg, MD 20878 240.937.5880 [email protected]
XML 30 R12.htm IDEA: XBRL DOCUMENT v3.25.3 Licensing Agreements 9 Months Ended Sep. 30, 2025 Organization, Consolidation and Presentation of Financial Statements [Abstract]   Licensing Agreements 4. Licensing Agreements D&D Pharmatech Inc. License and Collaboration Agreement In April 2023, we entered into a license and collaboration agreement with D&D Pharmatech Inc. (D&D), which was amended in May 2023, and further amended in March 2024 (the License Agreement). We were granted an exclusive, worldwide, sublicensable license to exploit licensed compounds and products under the
About — Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact We are Neuraly. Neuraly is a clinical-stage biotechnology company whose mission is to translate scientific discoveries in neurology into new drugs that can radically improve and prolong the lives of people suffering from the devastating consequences of diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD) and other neurodegenerative disorders. The company
CORRECTING and REPLACING Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease – Boston Harbor Angels >"/> Search Home About Us Celebrates 20 Years of Angel Investing Letter to Founders Facts Management Team Internship Program For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner For Founders What Industries? Where Do We Invest? Apply! Schedule Consultation with Z! Boston Harbor Angels Lighthouse What Founders Say! Portfolio Portfolio Store News New … anagement Team Internship Program For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner For Founders What Industries? Where Do We Invest? Apply! Schedule Consultation with Z! Boston Harbor Angels Lighthouse What Founders Say! Portfolio Portfolio Store News News LinkedIn Media Podcast Contact Us Home News Portfolio News CORRECTING and REPLACING Neuraly Announces First Patient Dosed in Phase 2 C … e About Us Portfolio News Contact For Investors Membership Resources The Active Fund The EQX Fund Co-Invest with Boston Harbor Angels Boston Harbor Angels Captain’s Dinner Follow Us Facebook Linkedin Copyright © 2023. Boston Harbor Angels. All Rights Reserved. This website is created and maintained by Business IT Essentials Manage Cookie Consent We use cookies to optimize our website and our service. Functional Functional Always active The technical storage or access is
Neuraly, Inc. Supports Phase 2 Investigator-Initiated Trial of Pegsebrenatide (NLY01) for Progressive Multiple Sclerosis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Neuraly, Inc. Supports Phase 2 Investigator-Initiated Trial of Pegsebrenatide (NLY01) for Progressive Multiple Sclerosis May 5, 2026 | 3 min read Twitter LinkedIn Facebook Email Print GAITHERSBURG, Md.--(BUSINESS WIRE)-- Neuraly, Inc ., a wholly owned subsidiary of D&D Pharmatech, Inc. (KOSDAQ: 347850 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuraly, Enigma Biomedical sign deal for PET imaging biomarker Skip to site menu Skip to page content Switch language: .translate --> MD Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Diagnostic Imaging Patient Monitoring Manufacturing Materials Treatments Medical Devices Anesthesia and Respiratory Devices Cardiovascular Dental Devices Diabetes Care Devices Nephrology and Urology Devices Neurology Devices Ophthalmic Devices Orthopedic Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability I
Enigma to use Neuraly's PET tracer for monitoring MS neuroinflammation Skip to content Newsletter Search Search for: Search Toggle navigation Search for: Search About MS Toggle menu: About MS Multiple sclerosis overview Causes and risk factors Symptoms Diagnosis Prognosis Treatments options for MS Approved treatments Experimental treatments Stem cell therapy Types of MS RRMS SPMS PPMS CIS Living with Toggle menu: Living with Living with MS Mental health McDonald criteria Foods to eat and avoid Exercise MS hug Cannabis and MS MS spasticity Heat sensitivity MS in men MS in women Support and
Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NYL01 for Patients with Parkinson’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trend … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NYL01 for Patients with Parkinson’s Disease March 3, 2020 | 3 min read Twitter LinkedIn Facebook Email Print Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative dis … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Startup Neuraly Launches with $36 Million: Targets Neurodegenerative Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Op … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Startup Neuraly Launches with $36 Million: Targets Neurodegenerative Diseases July 18, 2018 | 2 min read | Alex Keown Twitter LinkedIn Facebook Email Print Maryland-based Neuraly surged forth from the startup gate with $36 million in Series A funding that will finance the … o & Pharma. Two U.S.-based funds, Octave Life Sciences and Maryland Venture Fund, also participated in this financing, the company said. As part of the funding agreement, John Ku, executive vice president of Smilegate Investment, Phillip Jung, an associate at Maryland Venture Fund, Junghee Lim, executive managing director of InterVest and Keele Park, CEO of Magna Investment, will assume positions on the Neuraly board of directors. Twitter LinkedIn Facebook Email Print Cli … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact We discover and develop revolutionary treatments for neurodegenerative diseases We’re in the business of offering new hope. Neuraly was founded to develop new drugs that change our expectations about successful treatment of progressive diseases like Alzheimer’s and Parkinson’s. We are developing drugs that address new pathways, capitalize on our founder’s innovation, and deliver med
Team — Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Team Leadership Team Seulki Lee, PhD CEO Dr. Lee, founder, is an expert in drug and protein delivery. His research is focused on identifying novel targets critically involved in the origination of the disease. He invented NLY01 and, in collaboration with Dr. Ted Dawson’s team, at John’s Hopkins School of Medicine, proved its exceptional neuroprotective activity in anima
Careers — Neuraly 0 Skip to Content About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Open Menu Close Menu About Pipeline Science Team News Careers Contact Careers Thank you for visiting our careers page. For a full list of our open positions please click here . Privacy Policy © Copyright 2023, Neuraly Inc 704 Quince Orchard Road #320 Gaithersburg, MD 20878 240.937.5880 [email protected]